Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -27,520 | -15,387 | -9,609 | -4,650 | -19,029 |
| Depreciation Amortization | 26 | 20 | 13 | 7 | 177 |
| Accounts receivable | N/A | N/A | N/A | N/A | 40 |
| Accounts payable and accrued liabilities | 272 | 1,329 | 876 | 479 | -504 |
| Other Working Capital | 205 | 1,333 | 591 | 723 | 235 |
| Other Operating Activity | 7,869 | -1,097 | -792 | -426 | 996 |
| Operating Cash Flow | $-19,148 | $-13,803 | $-8,921 | $-3,867 | $-18,085 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -37,004 | 1,758 | -769 | -3,312 | 11,671 |
| PPE Investments | N/A | N/A | N/A | N/A | -14 |
| Investing Cash Flow | $-37,004 | $1,758 | $-769 | $-3,312 | $11,657 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 103,478 | 3,793 | 3,611 | 398 | 8,544 |
| Other Financing Activity | 0 | 0 | 0 | -31 | -139 |
| Financing Cash Flow | $103,478 | $3,793 | $3,611 | $367 | $8,405 |
| Beginning Cash Position | 9,165 | 9,165 | 9,165 | 9,165 | 7,189 |
| End Cash Position | 56,491 | 913 | 3,087 | 2,353 | 9,165 |
| Net Cash Flow | $47,325 | $-8,252 | $-6,079 | $-6,812 | $1,977 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,148 | -13,803 | -8,921 | -3,867 | -18,085 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -14 |
| Free Cash Flow | -19,148 | -13,803 | -8,921 | -3,867 | -18,099 |